Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Karen K. Yam, Angela Brewer, Virginie Bleau, Édith Beaulieu, Corey P. Mallett & Brian J. Ward. (2017) Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice. Human Vaccines & Immunotherapeutics 13:3, pages 561-571.
Read now
Read now
Nathalie Garçon & Alberta Di Pasquale. (2017) From discovery to licensure, the Adjuvant System story. Human Vaccines & Immunotherapeutics 13:1, pages 19-33.
Read now
Read now
Crina Stavaru, Adrian Onu, Emilia Lupulescu, Catalin Tucureanu, Orhan Rasid, Ene Vlase, Cristin Coman, Iuliana Caras, Alina Ghiorghisor, Laurentiu Berbecila, Vlad Tofan, Richard A. Bowen, Nicole Marlenee, Airn Hartwig, Helle Bielefeldt-Ohmann, Susan L. Baldwin, Neal Van Hoeven, Thomas S. Vedvick, Chuong Huynh, Michael K. O'Hara, Diana L. Noah & Christopher B. Fox. (2016) Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Human Vaccines & Immunotherapeutics 12:4, pages 1009-1026.
Read now
Read now
Giuseppe Del Giudice, Elena Fragapane, Giovanni Della Cioppa & Rino Rappuoli. (2013)
Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opinion on Biological Therapy 13:1, pages 121-135.
Read now
Read now
Hideyuki Ikematsu, Kazuyoshi Tenjinbaru, Ping Li, Anuradha Madan & David Vaughn. (2012) Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Human Vaccines & Immunotherapeutics 8:8, pages 1119-1125.
Read now
Read now
Nicola Principi & Susanna Esposito. (2012) Adjuvanted influenza vaccines. Human Vaccines & Immunotherapeutics 8:1, pages 59-66.
Read now
Read now
Derek T O’Hagan, Rino Rappuoli, Ennio De Gregorio, Theodore Tsai & Giuseppe Del Giudice. (2011) MF59 adjuvant: the best insurance against influenza strain diversity. Expert Review of Vaccines 10:4, pages 447-462.
Read now
Read now
Holly Sanders & Ian M Feavers. (2011) Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Review of Vaccines 10:3, pages 323-334.
Read now
Read now
Articles from other publishers (48)
Javier Castrodeza-Sanz, Iván Sanz-Muñoz & Jose M. Eiros. (2023) Adjuvants for COVID-19 Vaccines. Vaccines 11:5, pages 902.
Crossref
Crossref
Allegra Peletta, Céline Lemoine, Thomas Courant, Nicolas Collin & Gerrit Borchard. (2023) Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccines. Pharmacological Research 189, pages 106699.
Crossref
Crossref
Soumik Barman, Dheeraj Soni, Byron Brook, Etsuro Nanishi & David J. Dowling. (2022) Precision Vaccine Development: Cues From Natural Immunity. Frontiers in Immunology 12.
Crossref
Crossref
Derek T. O’Hagan, Robbert van der Most, Rushit N. Lodaya, Margherita Coccia & Giuseppe Lofano. (2021) “World in motion” – emulsion adjuvants rising to meet the pandemic challenges. npj Vaccines 6:1.
Crossref
Crossref
Sonia Jangra, Jeffrey J. Landers, Raveen Rathnasinghe, Jessica J. O’Konek, Katarzyna W. Janczak, Marilia Cascalho, Andrew A. Kennedy, Andrew W. Tai, James R. BakerJr.Jr., Michael Schotsaert & Pamela T. Wong. (2021) A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine. Frontiers in Immunology 12.
Crossref
Crossref
Jennifer Connors, Matthew R. Bell, Jennifer Marcy, Michele Kutzler & Elias K. Haddad. (2021) The impact of immuno-aging on SARS-CoV-2 vaccine development. GeroScience 43:1, pages 31-51.
Crossref
Crossref
Zhuofan Li, Yiwen Zhao, Yibo Li & Xinyuan Chen. (2021) Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines 9:2, pages 75.
Crossref
Crossref
Aristine Cheng, Szu-Min Hsieh, Sung-Ching Pan, Yu-Han Li, Erh-Fang Hsieh, Hsiang-Chi Lee, Ting-Wan Lin, Kuan-Lang Lai, Charles Chen, Stanley Shi-Chung Chang & Shan-Chwen Chang. (2019) The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial. Journal of Microbiology, Immunology and Infection 52:5, pages 685-692.
Crossref
Crossref
Teena Mohan, Wandi Zhu, Ye Wang & Bao-Zhong Wang. (2018) Applications of chemokines as adjuvants for vaccine immunotherapy. Immunobiology 223:6-7, pages 477-485.
Crossref
Crossref
L.H. Martín Arias, R. Sanz Fadrique, M. Sáinz Gil & M.E. Salgueiro-Vazquez. (2017) Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations. Vaccine 35:37, pages 4870-4876.
Crossref
Crossref
Xiangjie Sun, Jessica A. Belser, Joanna A. Pulit-Penaloza, Hannah M. Creager, Zhu Guo, Stacie N. Jefferson, Feng Liu, Ian A. York, James Stevens, Taronna R. Maines, Daniel B. Jernigan, Jacqueline M. Katz, Min Z. Levine & Terrence M. Tumpey. (2017) Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets. Virology 508, pages 164-169.
Crossref
Crossref
Kinnera E. Chada, Richard Forshee, Hana Golding, Steven Anderson & Hong Yang. (2017) A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines. Vaccine 35:24, pages 3162-3170.
Crossref
Crossref
Ailian Zhang, Yu Yang, Yan Wang, Gan Zhao, Xiumei Yang, Danyang Wang & Bin Wang. (2017) Adjuvant-active aqueous extracts from Artemisia rupestris L. improve immune responses through TLR4 signaling pathway. Vaccine 35:7, pages 1037-1045.
Crossref
Crossref
Leora R. Feldstein, Laura Matrajt, M. Elizabeth Halloran, Wendy A. Keitel & Ira M. LonginiJr.Jr.. (2016) Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine 34:33, pages 3796-3802.
Crossref
Crossref
Hui Li & Bin Cao. 2016. SARS, MERS and other Viral Lung Infections. SARS, MERS and other Viral Lung Infections
65
83
.
Feng Liu, Xiangjie Sun, Jeffery Fairman, David B. Lewis, Jacqueline M. Katz, Min Levine, Terrence M. Tumpey & Xiuhua Lu. (2016) A cationic liposome–DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets. Virology 492, pages 197-203.
Crossref
Crossref
Karen K. Yam, Jyotsana Gupta, Elizabeth K. Allen, Kayla R. Burt, Édith Beaulieu, Corey P. Mallett, David S. Burt & Brian J. Ward. (2016) Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. Vaccine 34:12, pages 1444-1451.
Crossref
Crossref
Lawrence Segal, Sandrine Wouters, Danielle Morelle, Gaëlle Gautier, Julien Le Gal, Thomas Martin, Frieke Kuper, Eric Destexhe, Arnaud M. Didierlaurent & Nathalie Garçon. (2015) Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. Journal of Applied Toxicology 35:12, pages 1564-1576.
Crossref
Crossref
Jesse L. Goodman. (2015) Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics. Clinical Infectious Diseases, pages civ957.
Crossref
Crossref
Lawrence Segal, Virginie Roger, Colin Williams, Eric Destexhe & Nathalie Garçon. (2015) Effects of Adjuvant Systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats. Regulatory Toxicology and Pharmacology 73:1, pages 116-125.
Crossref
Crossref
Olivier Godeaux, Patricia Izurieta, Miguel Madariaga, Mamadou Dram?Ping Li & David W. Vaughn. (2015) Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years. Vaccine 33:18, pages 2189-2195.
Crossref
Crossref
Javier Díez-Domingo, José-María Baldó, Maria Victoria Planelles-Catarino, María Garcés-Sánchez, Isabel Ubeda, Angels Jubert-Rosich, Josep Marès, Pilar Garcia-Corbeira, Philippe Moris, Maurice Teko, Carline Vanden Abeele & Paul Gillard. (2015) Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza and Other Respiratory Viruses 9:2, pages 68-77.
Crossref
Crossref
Pope Kosalaraksa, Robert Jeanfreau, Louise Frenette, Mamadou Drame, Miguel Madariaga, Bruce L. Innis, Olivier Godeaux, Patricia Izurieta & David W. Vaughn. (2015) AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial. The Journal of Infectious Diseases 211:5, pages 801-810.
Crossref
Crossref
Viktoriya Sokolova, Astrid Maria Westendorf, Jan Buer, Klaus Überla & Matthias Epple. (2015) The potential of nanoparticles for the immunization against viral infections. Journal of Materials Chemistry B 3:24, pages 4767-4779.
Crossref
Crossref
Ruchi R. Shah, Luis A. Brito, Derek T. O’Hagan & Mansoor M. Amiji. 2015. Subunit Vaccine Delivery. Subunit Vaccine Delivery
59
76
.
Paul Gillard, Daniel Wai Sing Chu, Shinn-Jang Hwang, Pan-Chyr Yang, Prasert Thongcharoen, Fong Seng Lim, Mamadou Dramé, Karl Walravens & François Roman. (2014) Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infectious Diseases 14:1.
Crossref
Crossref
Christopher H. CleggRichard RoqueNeal Van HoevenLucy PerroneSusan L. BaldwinJoseph A. RiningerRichard A. Bowen & Steven G. Reed. (2012) Adjuvant solution for pandemic influenza vaccine production. Proceedings of the National Academy of Sciences 109:43, pages 17585-17590.
Crossref
Crossref
Annebel R. De Vleeschauwer, Benoît Baras, Constantinos S. Kyriakis, Valérie Jacob, Camille Planty, Sandra L. Giannini, Sally Mossman & Kristien Van Reeth. (2012) Efficacy of an AS03A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs. Vaccine 30:37, pages 5557-5563.
Crossref
Crossref
Pan-Chyr Yang, Chong-Jen Yu, Shan-Chwen Chang, Szu-Min Hsieh, Mamadou Drame, Karl Walravens, Fran?ois Roman & Paul Gillard. (2012) Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. Journal of the Formosan Medical Association 111:6, pages 333-339.
Crossref
Crossref
Mariana Baz, Mukesh Samant, Hakima Zekki, Pascale Tribout-Jover, Martin Plante, Anne-Marie Lanteigne, Marie-Eve Hamelin, Corey Mallett, Barbara Papadopoulou & Guy Boivin. (2012) Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice. Clinical and Vaccine Immunology 19:2, pages 209-218.
Crossref
Crossref
Libo Dong, Feng Liu, Jeffery Fairman, David K. Hong, David B. Lewis, Thomas Monath, John F. Warner, Jessica A. Belser, Jenish Patel, Kathy Hancock, Jacqueline M. Katz & Xiuhua Lu. (2012) Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine 30:2, pages 254-264.
Crossref
Crossref
Jessica A. Belser, Cynthia B. Snider, Nancy J. Cox & Frederick G. Hayden. (2011) XIth International Symposium on Respiratory Viral Infections. Influenza and Other Respiratory Viruses 5:6, pages 443-e457.
Crossref
Crossref
Yuichi Harada, Ai Ninomiya-Mori, Yoshimasa Takahashi, Masayuki Shirakura, Noriko Kishida, Tsutomu Kageyama, Yoshikazu Tada, Masato Tashiro & Takato Odagiri. (2011) Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine 29:46, pages 8330-8337.
Crossref
Crossref
John Steel. (2012) New Strategies for the Development of H5N1 Subtype Influenza Vaccines. BioDrugs 25:5, pages 285-298.
Crossref
Crossref
G. Kuether, B. Dietrich, T. Smith, C. Peter & S. Gruessner. (2011) Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination. Vaccine 29:40, pages 6830-6833.
Crossref
Crossref
Joanne M. Langley, George Risi, Michael Caldwell, Larry Gilderman, Bruce Berwald, Charles Fogarty, Terry Poling, Dennis Riff, Mira Baron, Louise Frenette, Eric Sheldon, Harry Collins, Marc Shepard, Marc Dionne, Daniel Brune, Linda Ferguson, David Vaughn, Ping Li & Louis Fries. (2011) Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study. The Journal of Infectious Diseases 203:12, pages 1729-1738.
Crossref
Crossref
Garry L. Morefield. (2011) A Rational, Systematic Approach for the Development of Vaccine Formulations. The AAPS Journal 13:2, pages 191-200.
Crossref
Crossref
Alexander Batista-Duharte, Erik B. Lindblad & Ernesto Oviedo-Orta. (2011) Progress in understanding adjuvant immunotoxicity mechanisms. Toxicology Letters 203:2, pages 97-105.
Crossref
Crossref
Sven Meyer, Matti Adam, Brunhilde Schweiger, Corina Ilchmann, Christine Eulenburg, Edgar Sattinger, Hendrik Runte, Michael Schlüter, Tobias Deuse, Hermann Reichenspurner & Angelika Costard-Jäckle. (2011) Antibody Response After a Single Dose of an AS03-Adjuvanted Split-Virion Influenza A (H1N1) Vaccine in Heart Transplant Recipients. Transplantation 91:9, pages 1031-1035.
Crossref
Crossref
Heng Liu, Laura Bungener, Wouter ter Veer, Beth-Ann Coller, Jan Wilschut & Anke Huckriede. (2011) Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 29:11, pages 2037-2043.
Crossref
Crossref
Beno?t Baras, Koert J. Stittelaar, Thijs Kuiken, Val?rie Jacob, Roger Bernhard, Sandra Giannini, Leon de Waal, Geert van Amerongen, James H. Simon, Albert D.M.E. Osterhaus, Emmanuel Hanon & Sally P. Mossman. (2011) Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 29:11, pages 2092-2099.
Crossref
Crossref
Maja Folkenberg, Torbj?rn Callr?us, Henrik Svanstr?m, Palle Valentiner-Branth & Anders Hviid. (2011) Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009?March 2010. Vaccine 29:6, pages 1180-1184.
Crossref
Crossref
Giuseppe Del Giudice & Rino Rappuoli. 2011. Influenza Vaccines for the Future. Influenza Vaccines for the Future
401
423
.
Derek T. O’Hagan, Theodore Tsai & Steven Reed. 2011. Influenza Vaccines for the Future. Influenza Vaccines for the Future
327
357
.
Felix Geeraedts & Anke Huckriede. 2011. Crossroads between Innate and Adaptive Immunity III. Crossroads between Innate and Adaptive Immunity III
161
174
.
Ari Balofsky, Nancy Agmon-Levin & Yehuda Shoenfeld. (2010) The new H1N1 and HPV vaccines and old fears. Current Opinion in Rheumatology 22:4, pages 431-436.
Crossref
Crossref
Alenka Kraigher & Veronika Učakar. (2010) Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10. Vaccine 28:33, pages 5467-5472.
Crossref
Crossref
M Lamine Mbow, Ennio De Gregorio, Nicholas M Valiante & Rino Rappuoli. (2010) New adjuvants for human vaccines. Current Opinion in Immunology 22:3, pages 411-416.
Crossref
Crossref